# Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

> **NCT07431398** · PHASE1 · RECRUITING · sponsor: **Fulcrum Therapeutics** · enrollment: 24 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Pociredir

## Key facts

- **NCT ID:** NCT07431398
- **Lead sponsor:** Fulcrum Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-13
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-06
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07431398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07431398, "Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07431398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*